Pandemic influenza vaccine(Wuhan Institute of Biological Products)

This study is a single-center, randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety and preliminary immunogenicity of the pandemic influenza whole virus inactivated vaccine after intramuscular injection in healthy Chinese subjects aged 12 to 60 years according to a 0-21 day immunization schedule.